Circulating small extracellular vesicles in Alzheimer’s disease: a case–control study of neuro-inflammation and synaptic dysfunction
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disease characterized by Aβ plaques and neurofibrillary tangles. Chronic inflammation and synaptic dysfunction lead to disease progression and cognitive decline. Small extracellular vesicles (sEVs) are implicated in AD progression by facilitating the spread of pathological proteins and inflammatory cytokines. This study investigates synaptic dysfunction and neuroinflammation protein markers in plasma-derived sEVs (PsEVs), their association with Amyloid-β and tau pathologies, and their correlation with AD progression. Methods: A total of 90 [AD = 35, mild cognitive impairment (MCI) = 25, and healthy age-matched controls (AMC) = 30] participants were recruited. PsEVs were isolated using a chemical precipitation method, and their morphology was characterized by transmission electron microscopy. Using nanoparticle tracking analysis, the size and concentration of PsEVs were determined. Antibody-based validation of PsEVs was done using CD63, CD81, TSG101, and L1CAM antibodies. Synaptic dysfunction and neuroinflammation were evaluated with synaptophysin, TNF-α, IL-1β, and GFAP antibodies. AD-specific markers, amyloid-β (1–42), and p-Tau were examined within PsEVs using Western blot and ELISA. Results: Our findings reveal higher concentrations of PsEVs in AD and MCI compared to AMC (p < 0.0001). Amyloid-β (1–42) expression within PsEVs is significantly elevated in MCI and AD compared to AMC. We could also differentiate between the amyloid-β (1–42) expression in AD and MCI. Similarly, PsEVs-derived p-Tau exhibited elevated expression in MCI compared with AMC, which is further increased in AD. Synaptophysin exhibited downregulated expression in PsEVs from MCI to AD (p = 0.047) compared to AMC, whereas IL-1β, TNF-α, and GFAP showed increased expression in MCI and AD compared to AMC. The correlation between the neuropsychological tests and PsEVs-derived proteins (which included markers for synaptic integrity, neuroinflammation, and disease pathology) was also performed in our study. The increased number of PsEVs correlates with disease pathological markers, synaptic dysfunction, and neuroinflammation. Conclusions: Elevated PsEVs, upregulated amyloid-β (1–42), and p-Tau expression show high diagnostic accuracy in AD. The downregulated synaptophysin expression and upregulated neuroinflammatory markers in AD and MCI patients suggest potential synaptic degeneration and neuroinflammation. These findings support the potential of PsEV-associated biomarkers for AD diagnosis and highlight synaptic dysfunction and neuroinflammation in disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Instead, ongoing clinical trial studies are investigating EVs’ cargo, such as Aβ and tau proteins, for potential AD markers, due to their superior sensitivity, specificity, and accessibility in saliva, blood, and other body fluids [224,225].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [225]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 1×
“PsEVs were isolated, characterized, and validated following Minimal Information for Studies of Extracellular Vesicles (MISEV) 2018 guidelines, which suggest a protocol for documenting work specifically with extracellular vesicles [56].”
MethodThe biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770 · cited 1×
“It is well known that sEVs play a pivotal role in the progression of disease pathologies in neurodegenerative and metabolic diseases [33, 84].”
BackgroundComprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789 · cited 1×
“Synaptic dysfunction interacts with other core pathophysiology events of AD, such as the amyloid-β cascade, tau pathology, and neuroinflammation, eventually progressing to irreversible neurodegeneration and atrophy [72, 73].”
BackgroundPegtel, D. M., & Gould, S. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111902 · Cited by 2,682
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606 · cited 3×
“The pathological hallmark of AD, amyloid-β plaques, originates from the imprecise cleavage of the amyloid precursor protein (APP) by β-secretase (BACE1) and γ-secretase generating amyloid-β peptide forms [6–9].”
BackgroundInflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · cited 1×
“IL-1β, a potent immunomodulating cytokine, has previously been identified as a trigger for various inflammatory mediators in astrocytes and neurons [76].”
BackgroundAmyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965 · cited 1×
“The pathological hallmark of AD, amyloid-β plaques, originates from the imprecise cleavage of the amyloid precursor protein (APP) by β-secretase (BACE1) and γ-secretase generating amyloid-β peptide forms [6–9].”
BackgroundThe Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
Neuroinflammation: The Devil Is in the Details
DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591 · cited 1×
“On the other hand, they also have the potential to participate in the propagation and aggregation of misfolded proteins, particularly implicated in the pathological spread of Tau aggregates as indicated by both in vitro and in vivo studies [43].”
BackgroundEctosomes and exosomes: shedding the confusion between extracellular vesicles
Cocucci, E., & Meldolesi, J. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.01.004 · Cited by 1,435 · cited 1×
“For their functions in various physiological and pathological circumstances, sEVs are the most extensively researched type of EV [36–38]. sEVs exchange information between cells by transferring bioactive components (nucleic acids and proteins) [39].”
BackgroundMolecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994 · cited 1×
“Synaptic dysfunction interacts with other core pathophysiology events of AD, such as the amyloid-β cascade, tau pathology, and neuroinflammation, eventually progressing to irreversible neurodegeneration and atrophy [72, 73].”
BackgroundNeuroinflammation: The role and consequences
Lyman, M., Lloyd, D. G., Ji, X., Vizcaychipi, M. P., & Ma, D. (2014) · Neuroscience Research · doi:10.1016/j.neures.2013.10.004 · Cited by 730 · cited 1×
“The progressive neurodegenerative condition known as Alzheimer’s disease (AD) is characterized by cognitive decline as a result of the formation of amyloid-β (Aβ) plaques, neurofibrillary tangles (NFTs), and chronic neuroinflammation that leads to neurodegeneration [1–3].”
BackgroundHe, Z., Guo, J. L., McBride, J. D., Narasimhan, S., Kim, H., Changolkar, L., Zhang, B., Gathagan, R. J., Yue, C., Dengler, C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4443 · Cited by 645
Ng, A., Tam, W. W., Zhang, M. W., Ho, C. S., Husain, S. F., McIntyre, R. S., & Ho, R. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-30487-6 · Cited by 572 · cited 1×
“…elevated levels of these neuroinflammatory markers could be due to the activation of astrocytes and microglia and the subsequent increase in the secretion of PsEVs containing proinflammatory proteins, which suggests prominent neuroinflammatory conditions that may contribute to neuronal damage [57].”
BackgroundSZE, C.-I., TRONCOSO, J. C., KAWAS, C., MOUTION, P., PRICE, D. L., & MARTIN, L. J. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00011 · Cited by 562 · cited 3×
“This suggests synaptic degeneration, which has also been discussed in several studies [59, 63, 64].”
BackgroundResultBanks, W. A., Sharma, P., Bullock, K. M., Hansen, K. M., Ludwig, N., & Whiteside, T. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124407 · Cited by 561 · cited 1×
“As the sEVs’ composition bears the molecular signature of the secreting cell and bears an intrinsic property of transversing the blood–brain barrier (BBB) in both directions [40, 41], they are a target of constant research in neurodegenerative disease.”
BackgroundAlzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Sardar Sinha, M., Ansell-Schultz, A., Civitelli, L., Hildesjö, C., Larsson, M., Lannfelt, L., Ingelsson, M., & Hallbeck, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1868-1 · Cited by 527
Shen, J., & Kelleher, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608332104 · Cited by 485 · cited 1×
“Many point mutations in APP and γ-secretase cause familial early-onset AD, favoring Aβ42 formation, causing amyloid-β peptides prone to aggregate as fibrils and plaques [9, 11– 14].”
BackgroundAn Inflammation-Centric View of Neurological Disease: Beyond the Neuron
Skaper, S. D., Facci, L., Zusso, M., & Giusti, P. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00072 · Cited by 457
Chatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01137-1 · Cited by 439 · cited 2×
“According to research on animal and cell models, reactive astrocytes encircle and penetrate amyloid-β plaques, contributing to the amyloid-β pathological process [82, 83].”
BackgroundSelf-citationDecreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease
Goetzl, E. J., Kapogiannis, D., Schwartz, J. B., Lobach, I. V., Goetzl, L., Abner, E. L., Jicha, G. A., Karydas, A. M., Boxer, A., & Miller, B. L. (2016) · The FASEB Journal · doi:10.1096/fj.201600816r · Cited by 398
Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils
Gu, L., & Guo, Z. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12202 · Cited by 327 · cited 1×
“Primary amyloid-β peptide forms are Aβ40 and Aβ42, where the majority of the amyloid-β plaques in AD brains are composed of Aβ42 [10].”
Backgroundβ-Amyloid: the key peptide in the pathogenesis of Alzheimer’s disease
Sun, X., Chen, W.-D., & Wang, Y.-D. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00221 · Cited by 323
GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2023) · Cells · doi:10.3390/cells12091309 · Cited by 309 · cited 1×
“The cytoskeletal GFAP is found in astrocytic cells [80].”
BackgroundKamphuis, W., Mamber, C., Moeton, M., Kooijman, L., Sluijs, J. A., Jansen, A. H. P., Verveer, M., de Groot, L. R., Smith, V. D., Rangarajan, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042823 · Cited by 303 · cited 1×
“According to research on animal and cell models, reactive astrocytes encircle and penetrate amyloid-β plaques, contributing to the amyloid-β pathological process [82, 83].”
BackgroundExosomes in the Pathology of Neurodegenerative Diseases
Howitt, J., & Hill, A. F. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.757955 · Cited by 288
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models
Silva, M. C., Ferguson, F. M., Cai, Q., Donovan, K. A., Nandi, G., Patnaik, D., Zhang, T., Huang, H.-T., Lucente, D. E., Dickerson, B. C., et al. (2019) · eLife · doi:10.7554/elife.45457 · Cited by 283
Söllvander, S., Nikitidou, E., Brolin, R., Söderberg, L., Sehlin, D., Lannfelt, L., & Erlandsson, A. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0098-z · Cited by 267
Molecular genetics of Alzheimer’s disease
St George-Hyslop, P. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00301-7 · Cited by 265
Innate Immune Cell Death in Neuroinflammation and Alzheimer’s Disease
Rajesh, Y., & Kanneganti, T.-D. (2022) · Cells · doi:10.3390/cells11121885 · Cited by 262
Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
A. Frankola, K., H. Greig, N., Luo, W., & Tweedie, D. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794653751 · Cited by 251 · cited 1×
“TNF-α, another pro-inflammatory cytokine primarily secreted by activated macrophages and microglia, is recognized for its dual role in promoting cell survival and death in the central nervous system [78, 79].”
BackgroundTNF-mediated neuroinflammation is linked to neuronal necroptosis in Alzheimer's disease hippocampus
Jayaraman, A., Htike, T. T., James, R., Picon, C., & Reynolds, R. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01264-w · Cited by 236 · cited 1×
“TNF-α, another pro-inflammatory cytokine primarily secreted by activated macrophages and microglia, is recognized for its dual role in promoting cell survival and death in the central nervous system [78, 79].”
BackgroundNeuronal cell death mechanisms in Alzheimer’s disease: An insight
Goel, P., Chakrabarti, S., Goel, K., Bhutani, K., Chopra, T., & Bali, S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.937133 · Cited by 234 · cited 1×
“Aβ plaques activate immune receptors on microglia, thereby releasing pro-inflammatory cytokines and chemokines that mediate neuroinflammation, which, if it reaches a chronic level, causes damage to brain cells, including axonal demy-elination and synaptic pruning [17–23].”
BackgroundVella, L., Hill, A., & Cheng, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020173 · Cited by 230
Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B. (2018) · The FASEB Journal · doi:10.1096/fj.201700731r · Cited by 219 · cited 2×
“This suggests synaptic degeneration, which has also been discussed in several studies [59, 63, 64].”
BackgroundResultLleó, A., Núñez-Llaves, R., Alcolea, D., Chiva, C., Balateu-Paños, D., Colom-Cadena, M., Gomez-Giro, G., Muñoz, L., Querol-Vilaseca, M., Pegueroles, J., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001290 · Cited by 219 · cited 1×
“It is suggested to precede other pathophysiological events of AD rather than neurodegeneration, which manifests during the later stages of the disease [71].”
BackgroundRastogi, S., Sharma, V., Bharti, P. S., Rani, K., Modi, G. P., Nikolajeff, F., & Kumar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010440 · Cited by 174 · cited 4×
“…studies in MCI and AD, there is an increase in cross-talk between different pathophysiological processes, which leads to an increase in sEVs number and sEVs specific marker as a cellular response to heightened cellular stress aggravating neuronal damage and synaptic dysfunction [33, 63, 64].”
BackgroundInfluentialSelf-citationCurrent status on Alzheimer disease molecular genetics: from past, to present, to future
Bettens, K., Sleegers, K., & Van Broeckhoven, C. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq142 · Cited by 169 · cited 1×
“Many point mutations in APP and γ-secretase cause familial early-onset AD, favoring Aβ42 formation, causing amyloid-β peptides prone to aggregate as fibrils and plaques [9, 11– 14].”
BackgroundGámez-Valero, A., Campdelacreu, J., Vilas, D., Ispierto, L., Reñé, R., Álvarez, R., Armengol, M. P., Borràs, F. E., & Beyer, K. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0169-5 · Cited by 167 · cited 1×
“For their functions in various physiological and pathological circumstances, sEVs are the most extensively researched type of EV [36–38]. sEVs exchange information between cells by transferring bioactive components (nucleic acids and proteins) [39].”
BackgroundNeuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments
Jung, Y. J., Tweedie, D., Scerba, M. T., & Greig, N. H. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00313 · Cited by 151
Addenbrooke's cognitive examination III in the diagnosis of dementia: a critical review
Bruno, D., & Schurmann Vignaga, S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s151253 · Cited by 149 · cited 1×
“These tools evaluate verbal fluency and temporal orientation, although results may be influenced by subject bias [29–31].”
BackgroundGiacomucci, G., Mazzeo, S., Bagnoli, S., Ingannato, A., Leccese, D., Berti, V., Padiglioni, S., Galdo, G., Ferrari, C., Sorbi, S., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11055-5 · Cited by 147
Huo, L., Du, X., Li, X., Liu, S., & Xu, Y. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.738442 · Cited by 145 · cited 1×
“Thus, sEVs can be a compelling subject for the investigation to understand AD’s inflammation and synaptic dysfunction [48–52].”
BackgroundSubramanian, J., Savage, J. C., & Tremblay, M.-È. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.592607 · Cited by 127 · cited 1×
“Synapse loss is a crucial pathophysiological event in disease progression, and synaptic proteins have been extensively studied due to earlier perturbations [4, 5].”
BackgroundGomes, D. E., & Witwer, K. W. (2022) · Journal of Extracellular Biology · doi:10.1002/jex2.35 · Cited by 126 · cited 1×
“We employed the neuronal protein L1CAM as a marker to ascertain the neuronal origin, although there is a debate surrounding its specificity for neuronal origin [62].”
MethodTau as a Biomarker of Neurodegeneration
Holper, S., Watson, R., & Yassi, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137307 · Cited by 126
Synapse Loss Induced by Interleukin-1β Requires Pre- and Post-synaptic Mechanisms
Mishra, A., Kim, H. J., Shin, A. H., & Thayer, S. A. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9342-7 · Cited by 121 · cited 1×
“Synapse loss is a crucial pathophysiological event in disease progression, and synaptic proteins have been extensively studied due to earlier perturbations [4, 5].”
BackgroundInterleukin-1 and the Immunogenetics of Alzheimer Disease
Mrak, R. E., & Griffin, W. S. T. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.6.471 · Cited by 119 · cited 1×
“Consistent evidence from post-mortem AD brain studies indicates the prevalent overexpression of IL-1β, with immunohistochemical analyses revealing its localization to microglia around plaques [77].”
BackgroundChen, Y., He, Y., Han, J., Wei, W., & Chen, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1258640 · Cited by 116
Exosomes as Carriers of Alzheimer's Amyloid-ß
Yuyama, K., & Igarashi, Y. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00229 · Cited by 114 · cited 1×
“In this study, we aimed to investigate the capacity of PsEVs to mirror pathological processes linked to AD and MCI. sEVs are extensively documented in the propagation of pathological processes associated with neurodegenerative and metabolic disorders [60].”
BackgroundMatías‐Guiu, J. A., Valles‐Salgado, M., Rognoni, T., Hamre-Gil, F., Moreno‐Ramos, T., & Matías‐Guiu, J. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000469658 · Cited by 107
Zyśk, M., Beretta, C., Naia, L., Dakhel, A., Påvénius, L., Brismar, H., Lindskog, M., Ankarcrona, M., & Erlandsson, A. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02722-z · Cited by 107 · cited 1×
“However, severe endosomal–lysosomal abnormalities arise in astrocytes when a significantly large amount of Aβ accumulates within astrocytes for a prolonged period without degradation [45, 46].”
BackgroundMicroglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimer’s disease
Gabrielli, M., Prada, I., Joshi, P., Falcicchia, C., D’Arrigo, G., Rutigliano, G., Battocchio, E., Zenatelli, R., Tozzi, F., Radeghieri, A., et al. (2022) · Brain · doi:10.1093/brain/awac083 · Cited by 106 · cited 1×
“Additionally, it has been found that the release of amyloid-β by microglia in association with large extracellular vesicles (Aβ-lEVs) damages synaptic plasticity and modifies the architecture of the dendritic spine [47].”
BackgroundHyperphosphorylation Renders Tau Prone to Aggregate and to Cause Cell Death
Liu, M., Sui, D., Dexheimer, T. S., Hovde, S., Deng, X., Wang, K., Lin, H. L., Hagar, H. C., Kweon, H. K., Kuo, N. S., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02034-w · Cited by 105 · cited 1×
“The combined effect of accumulation of NFTs, amyloid-β fibrils, and plaques leads to neuronal function loss and cell death [15, 16].”
BackgroundDevelopment and validation of a salivary tau biomarker in Alzheimer's disease
Pekeles, H., Qureshi, H. Y., Paudel, H. K., Schipper, H. M., Gornistky, M., & Chertkow, H. M. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.03.003 · Cited by 97
Mori, Y., Tsuji, M., Oguchi, T., Kasuga, K., Kimura, A., Futamura, A., Sugimoto, A., Kasai, H., Kuroda, T., Yano, S., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.653267 · Cited by 79 · cited 1×
“In addition to these, other proteins, including the neurofilament light (NFL) protein, glial fibrillary acidic protein (GFAP), and synaptic proteins, have also been identified as AD biomarkers [24–28].”
BackgroundZhou, F., Ebea, P. O., Mutai, E., Wang, H., Sukreet, S., Navazesh, S. E., Dogan, H., Li, W., Cui, J., Ji, P., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.838543 · Cited by 79 · cited 1×
“As the sEVs’ composition bears the molecular signature of the secreting cell and bears an intrinsic property of transversing the blood–brain barrier (BBB) in both directions [40, 41], they are a target of constant research in neurodegenerative disease.”
BackgroundNeuronally derived extracellular vesicles: an emerging tool for understanding Alzheimer’s disease
Watson, L. S., Hamlett, E. D., Stone, T. D., & Sims-Robinson, C. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0317-5 · Cited by 74 · cited 1×
“The increased secretion of sEVs, coupled with the transmission of disease-related pathologies through sEVs-associated cargo, makes sEVs a viable candidate for understanding the physiological state of their originating cells, which is reflected in sEVs cargo [61].”
BackgroundChoi, S.-B., Kwon, S., Kim, J.-H., Ahn, N.-H., Lee, J.-H., & Yang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411757 · Cited by 73
Beretta, C., Nikitidou, E., Streubel-Gallasch, L., Ingelsson, M., Sehlin, D., & Erlandsson, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-72355-2 · Cited by 71 · cited 1×
“Thus, sEVs can be a compelling subject for the investigation to understand AD’s inflammation and synaptic dysfunction [48–52].”
BackgroundQing, H., Li, N.-M., Liu, K.-F., Qiu, Y.-J., Zhang, H.-H., & Nakanishi, H. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.247469 · Cited by 66
Ferrer, I., Andrés‐Benito, P., Ausín, K., Pamplona, R., del Río, J. A., Fernández‐Irigoyen, J., & Santamaría, E. (2021) · Brain Pathology · doi:10.1111/bpa.12996 · Cited by 65 · cited 1×
“The combined effect of accumulation of NFTs, amyloid-β fibrils, and plaques leads to neuronal function loss and cell death [15, 16].”
BackgroundRani, K., Rastogi, S., Vishwakarma, P., Bharti, P. S., Sharma, V., Renu, K., Modi, G. P., Vishnu, V. Y., Chatterjee, P., Dey, A. B., et al. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108980 · Cited by 64 · cited 1×
“The PsEVs were extracted by chemical-based precipitation from the plasma samples of AD patients, MCI patients, and AMC, as discussed previously [53, 54].”
MethodSelf-citationThe Role of Astrocytes in Synapse Loss in Alzheimer's Disease: A Systematic Review
Hulshof, L. A., van Nuijs, D., Hol, E. M., & Middeldorp, J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.899251 · Cited by 64 · cited 1×
“GFAP is an activation marker of astroglia, and in AD, this activation is associated with synaptic dysfunction [58].”
BackgroundTargeting Microglia-Synapse Interactions in Alzheimer’s Disease
Piccioni, G., Mango, D., Saidi, A., Corbo, M., & Nisticò, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052342 · Cited by 63 · cited 1×
“Aβ plaques activate immune receptors on microglia, thereby releasing pro-inflammatory cytokines and chemokines that mediate neuroinflammation, which, if it reaches a chronic level, causes damage to brain cells, including axonal demy-elination and synaptic pruning [17–23].”
BackgroundGomes, P., Tzouanou, F., Skolariki, K., Vamvaka-Iakovou, A., Noguera-Ortiz, C., Tsirtsaki, K., Waites, C. L., Vlamos, P., Sousa, N., Costa-Silva, B., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114183 · Cited by 55 · cited 1×
“…associated with neurodegenerative diseases [32]. sEVs are bi-layered membrane vesicles that have a heterogeneous group of (< 200 nm in diameter) that are found in different human body fluids, including blood, urine, saliva, and ascites, and that are actively released by all cell types [33–35].”
BackgroundNeuronal-Derived EV Biomarkers Track Cognitive Decline in Alzheimer’s Disease
Eren, E., Leoutsakos, J.-M., Troncoso, J., Lyketsos, C. G., Oh, E. S., & Kapogiannis, D. (2022) · Cells · doi:10.3390/cells11030436 · Cited by 53 · cited 1×
“Moreover, sEVs exhibit a dual function in neurodegenerative processes, as sEVs not only play an essential role in clearing misfolded proteins, thereby exerting detoxifying effects and providing neuroprotection [42].”
BackgroundThe Role of Neuroinflammation in Neurodegenerative Disorders
Suescun, J., Chandra, S., & Schiess, M. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813832-8.00013-3 · Cited by 43 · cited 1×
“The progressive neurodegenerative condition known as Alzheimer’s disease (AD) is characterized by cognitive decline as a result of the formation of amyloid-β (Aβ) plaques, neurofibrillary tangles (NFTs), and chronic neuroinflammation that leads to neurodegeneration [1–3].”
BackgroundReactive Astrogliosis: Role in Alzheimer's Disease
Jain, P., Wadhwa, P. K., & Jadhav, H. R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150713104738 · Cited by 41 · cited 1×
“Increased plasma GFAP levels could result from “reactive astrogliosis,” another term for aberrant astrocytic function brought on by damage to neurons [81].”
BackgroundExtracellular vesicles in Alzheimer’s disease: from pathology to therapeutic approaches
Thakor, A., & Garcia-Contreras, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.343882 · Cited by 41
Ally, M., Sugarman, M. A., Zetterberg, H., Blennow, K., Ashton, N. J., Karikari, T. K., Aparicio, H. J., Frank, B. E., Tripodis, Y., Martin, B. M., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12492 · Cited by 37 · cited 1×
“PsEVs of GFAP were elevated in AD [27] and MCI (Fig.”
BackgroundRastogi, S., Rani, K., Rai, S., Singh, R., Sharma, V., Bharti, P. S., Kapoor, V., Vishwakarma, P., Batra, M., Rawat, S., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03031-1 · Cited by 36 · cited 4×
“Based on the initial volume of biofluid input, all samples were normalized, i.e., 180 μL and the sample loading dye (2 × Laemmle Sample buffer) was mixed with PsEVs sample, and 20 μL equal volume was loaded to run on an 8–12% SDS PAGE [53, 55].”
BackgroundMethodInfluentialSelf-citationSynaptic Pruning in Alzheimer’s Disease: Role of the Complement System
Brucato, F. H., & Benjamin, D. E. (2020) · Global Journal of Medical Research · doi:10.34257/gjmrfvol20is6pg1 · Cited by 30
Manolopoulos, A., Delgado‐Peraza, F., Mustapić, M., Pucha, K. A., Nogueras‐Ortiz, C. J., Daskalopoulos, A., Knight, D. D., Leoutsakos, J., Oh, E. S., Lyketsos, C. G., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1254834 · Cited by 28
Utz, J., Berner, J., Munoz, L. E., Oberstein, T. J., Kornhuber, J., i, M. H., Maler, J. M., & Spitzer, P. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.682115 · Cited by 27 · cited 2×
“Our study’s findings contra-dict J. Utz et al. (2021), which showed increased synapto-physin levels in microvesicles isolated from cerebrospinal fluid (CSF) in AD [28].”
BackgroundSmall Extracellular Vesicles’ miRNAs: Biomarkers and Therapeutics for Neurodegenerative Diseases
Lim, W. Q., Michelle Luk, K. H., Lee, K. Y., Nurul, N., Loh, S. J., Yeow, Z. X., Wong, Q. X., Daniel Looi, Q. H., Chong, P. P., How, C. W., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041216 · Cited by 25 · cited 1×
“For their functions in various physiological and pathological circumstances, sEVs are the most extensively researched type of EV [36–38]. sEVs exchange information between cells by transferring bioactive components (nucleic acids and proteins) [39].”
BackgroundBajpai, S., Upadhyay, A. D., Sati, H., Pandey, R., Chaterjee, P., & Dey, A. B. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s244707 · Cited by 23 · cited 1×
“These tools evaluate verbal fluency and temporal orientation, although results may be influenced by subject bias [29–31].”
BackgroundRai, S., Bharti, P. S., Singh, R., Rastogi, S., Rani, K., Sharma, V., Gorai, P. K., Rani, N., Verma, B., Reddy, T. J., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1174951 · Cited by 19 · cited 2×
“Based on the initial volume of biofluid input, all samples were normalized, i.e., 180 μL and the sample loading dye (2 × Laemmle Sample buffer) was mixed with PsEVs sample, and 20 μL equal volume was loaded to run on an 8–12% SDS PAGE [53, 55].”
BackgroundMethodSelf-citationSnellman, A., Ekblad, L. L., Koivumäki, M., Lindgrén, N., Tuisku, J., Perälä, M., Kallio, L., Lehtonen, R., Saunavaara, V., Saunavaara, J. P., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.826423 · Cited by 17 · cited 1×
“In this context, the synchronized exchange of proteins involved in these pathological processes between the CNS and neuronal-derived sEVs highlights the potential of sEVs as reliable carriers of pathophysiological cascade occurring at the pathological site [74].”
Background
Research works printed but not linked: 3
- Goetzl EJ Kapogiannis D Schwartz JB Lobach IV Goetzl L Abner EL Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease FASEB J 2016 30 12 4141 4148 10.1096/fj.201600816R 27601437 PMC5102122 · DOI · Paper page
- Kim KY Shin KY Chang KA GFAP as a potential biomarker for Alzheimer’s disease: a systematic review and meta-analysis Cells 2023 12 9 1309 10.3390/cells12091309 37174709 PMC10177296 · DOI · Paper page
- Kalluri R LeBleu VS The biology, function, and biomedical applications of exosomes Science 2020 367 6478 6977 10.1126/science.aau6977 PMC7717626 32029601 · DOI · Paper page
Cited by
Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review
Leipp, F., Vialaret, J., Mohaupt, P., Coppens, S., Jaffuel, A., Niehoff, A., Lehmann, S., & Hirtz, C. (2024) · Brain Communications · doi:10.1093/braincomms/fcae396 · Cited by 101
“138”
Extracellular vesicles: translational research and applications in neurology
Manolopoulos, A., Yao, P. J., & Kapogiannis, D. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01080-z · Cited by 63
“…principal amyloidogenic peptide in plaques, were found to be elevated in NDEVs from patients at all stages of Alzheimer disease, from the preclinical stage 33 through mild cognitive impairment 66,67 (MCI) to dementia 68,69 , and to increase in a stepwise fashion with clinical progression 33,68,70 .”
Dehghani, S., Ocakcı, O., Hatipoglu, P. T., Özalp, V. C., & Tevlek, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04825-5 · Cited by 55
Agnello, L., Gambino, C. M., Ciaccio, A. M., Salemi, G., Brighina, F., Ragonese, P., Piccoli, T., Blandino, V., Stefano, V. D., Cacciabaudo, F., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120248 · Cited by 23
Gonul, C. P., Karaçiçek, B., & Genç, Ş. (2025) · Developmental Neurobiology · doi:10.1002/dneu.22984 · Cited by 19
Metadata
- Authors
- Singh, R., Rai, S., Bharti, P. S., Zehra, S., Gorai, P. K., Modi, G. P., Rani, N., Dev, K., Inampudi, K. K., Y., V. V., Chatterjee, P., Nikolajeff, F., & Kumar, S.
- Affiliations
- All India Institute of Medical Sciences (IN)
- Indian Institute of Technology BHU (IN)
- Jamia Millia Islamia (IN)
- Luleå University of Technology (SE)
- Corresponding author
- Kumar, Saroj
- ORCID
- Venue
- BMC Medicine
- Published
- 2024-06-20
- Volume
- 22
- Issue
- 1
- Pages
- 254-254
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC11188177
- OpenAlex
- W4399860075
- Cited by
- 28
- References
- 81
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 1
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Council of Scientific and Industrial Research (09/006(0533)/2021-EMR-I)
- Department of Health Research , INDIA (YSS/2020/000158)
- Indian Council of Medical Research (2020-1194)
- Department of Health Research (GIA/2020/000595)
- Lulea University of Technology
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, small extracellular vesicles, plasma-derived extracellular vesicles, synaptic dysfunction, neuroinflammation, amyloid-beta, tau phosphorylation, synaptophysin, IL-1β, TNF-α, glial fibrillary acidic protein, mild cognitive impairment, disease progression biomarkers, CD63, CD81, TSG101, L1CAM
- MeSH terms
- Extracellular Vesicles, Neuroinflammatory Diseases, Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Synapses, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.